Actively Recruiting
A 24-week Prospective, Open-label, Multicenter, Single-arm rPMS Study in Real-world Setting for Atectura®
Led by Novartis Pharmaceuticals · Updated on 2025-08-11
600
Participants Needed
18
Research Sites
241 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This surveillance was designed as a prospective, open-label, multicenter, single-arm, non-interventional, observational study to evaluate the safety and effectiveness of Atectura inhalation capsule for up to 24 weeks under routine clinical practice.
CONDITIONS
Official Title
A 24-week Prospective, Open-label, Multicenter, Single-arm rPMS Study in Real-world Setting for Atectura®
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adolescents 12 years and older and adults diagnosed with asthma by a physician
- Patients prescribed Atectura inhalation capsule (150/80, 150/160, or 150/320 micrograms) via Breezhaler according to approved label
- Patients who have signed a consent form for data collection and use
- For patients under 18, consent and signature from a legal representative is required
You will not qualify if you...
- Patients with hypersensitivity to Atectura or any of its components
- Patients with hereditary lactose intolerance, Lapp lactose deficiency, or glucose-galactose malabsorption
- Patients experiencing acute asthma symptoms requiring short-acting bronchodilators
- Patients currently participating in other interventional clinical trials
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 18 locations
1
Novartis Investigative Site
Daegu, Dalseo gu, South Korea, 42602
Actively Recruiting
2
Novartis Investigative Site
Kangwon Do, Gangneung si, South Korea, 210 711
Completed
3
Novartis Investigative Site
Wŏnju, Gangwon-do, South Korea, 26426
Active, Not Recruiting
4
Novartis Investigative Site
Goyang-si, Gyeonggi-do, South Korea, 10380
Actively Recruiting
5
Novartis Investigative Site
Guri-si, Gyeonggi-do, South Korea, 471-701
Completed
6
Novartis Investigative Site
Jeonju, Jeollabuk-do, South Korea, 561 712
Actively Recruiting
7
Novartis Investigative Site
Iksan Si, Jeonlabuk Do, South Korea, 570-711
Actively Recruiting
8
Novartis Investigative Site
Daejeon, Korea, South Korea, 35015
Completed
9
Novartis Investigative Site
Busan, South Korea, 48108
Actively Recruiting
10
Novartis Investigative Site
Gyeongsangnam Do, South Korea, 630-522
Completed
11
Novartis Investigative Site
Jeju City, South Korea, 63241
Actively Recruiting
12
Novartis Investigative Site
Jinju, South Korea, 660-702
Actively Recruiting
13
Novartis Investigative Site
Seoul, South Korea, 04763
Actively Recruiting
14
Novartis Investigative Site
Seoul, South Korea, 05505
Actively Recruiting
15
Novartis Investigative Site
Seoul, South Korea, 06273
Actively Recruiting
16
Novartis Investigative Site
Seoul, South Korea, 137 707
Actively Recruiting
17
Novartis Investigative Site
Taegu, South Korea, 41944
Actively Recruiting
18
Novartis Investigative Site
Ulsan, South Korea, 44033
Actively Recruiting
Research Team
N
Novartis Pharmaceuticals
CONTACT
N
Novartis Pharmaceuticals
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here